Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP326330.RAYo90Mm8VNNKc_MjH2LREsZm3gouxMbc9eH_HUg2cqXk130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP326330.RAYo90Mm8VNNKc_MjH2LREsZm3gouxMbc9eH_HUg2cqXk130_provenance.
• NP885112.RAh47qGsjIRrkpt9d99qGRmIqIqorROK5K298VrJl-08M130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP885112.RAh47qGsjIRrkpt9d99qGRmIqIqorROK5K298VrJl-08M130_provenance.
• assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP897743.RAYyYJgHtEKcgquy1qA2jyZiDPO112btxxK_65Fmc1p-U130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP897743.RAYyYJgHtEKcgquy1qA2jyZiDPO112btxxK_65Fmc1p-U130_provenance.
• NP721897.RA9MIofKYbXk3gCK9bc4IcjD3QYw8W6vEuEf6Pa3KnOlM130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP721897.RA9MIofKYbXk3gCK9bc4IcjD3QYw8W6vEuEf6Pa3KnOlM130_provenance.
• NP890623.RAdYvr3BgaTapQwDioxOI9Zunnf0HPN5gPHr9HD9FUbSc130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP890623.RAdYvr3BgaTapQwDioxOI9Zunnf0HPN5gPHr9HD9FUbSc130_provenance.
• NP890646.RAR6RpMNTJBIRRtVP7tpz-hbuULzpwnB42PzEeH72ekU8130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP890646.RAR6RpMNTJBIRRtVP7tpz-hbuULzpwnB42PzEeH72ekU8130_provenance.
• NP890667.RAYU9gu_3-KOZzYFb7soTjlZ8YRSdPnk5M4Gtq7113YTU130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP890667.RAYU9gu_3-KOZzYFb7soTjlZ8YRSdPnk5M4Gtq7113YTU130_provenance.
• NP124289.RAY0Jv12EQj24nf2pweNdiO7w6t38tErkq_gBO4Iyh7_o130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP124289.RAY0Jv12EQj24nf2pweNdiO7w6t38tErkq_gBO4Iyh7_o130_provenance.
• assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP675437.RAaXr71sGT58RsoHadDjpjTiOopQUu-_okYB0Rsd_TtVY130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675437.RAaXr71sGT58RsoHadDjpjTiOopQUu-_okYB0Rsd_TtVY130_provenance.
• NP890642.RAiiejW-1FBxX-K_aawjJl3AWWDbFqoUxT9pJtgK_FYVM130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP890642.RAiiejW-1FBxX-K_aawjJl3AWWDbFqoUxT9pJtgK_FYVM130_provenance.
• NP124767.RA2iGoQY_HQhsEa91q3Oif7_4FZOyLgRqwKCideE1McwE130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP124767.RA2iGoQY_HQhsEa91q3Oif7_4FZOyLgRqwKCideE1McwE130_provenance.
• NP675434.RAEydBm7n8-ArtSYPpIPqlmJvALSLP3YOCevozgFsztxU130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675434.RAEydBm7n8-ArtSYPpIPqlmJvALSLP3YOCevozgFsztxU130_provenance.
• NP675438.RAFCkB3V_KP8s83Jxqumjz_d0cNnW3wEUDJGsFnUC7wOk130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675438.RAFCkB3V_KP8s83Jxqumjz_d0cNnW3wEUDJGsFnUC7wOk130_provenance.
• NP675439.RAH7YnXYxiCh0pvQuKa37OQ-zwgGIwgp7ToLqsXirqztg130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675439.RAH7YnXYxiCh0pvQuKa37OQ-zwgGIwgp7ToLqsXirqztg130_provenance.
• NP675435.RAwbTOM0Lil8A3oyuZUX_CumDvyEY9r7DBF4nEqdyhlro130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675435.RAwbTOM0Lil8A3oyuZUX_CumDvyEY9r7DBF4nEqdyhlro130_provenance.
• NP675436.RA6KV837q9Msq2jsstoeKWd-SgzUOlTL0npyOQHRWmneA130_assertion description "[We examined the association between this SLCO1B3 polymorphism and time from ADT to androgen independence, ADT to prostate-specific antigen (PSA) nadir and PSA nadir to androgen independence in 68 Caucasian patients with advanced prostate cancer who were treated with ADT with metastatic disease (D2) or biochemical failure with no metastatic disease (D0).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP675436.RA6KV837q9Msq2jsstoeKWd-SgzUOlTL0npyOQHRWmneA130_provenance.